Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recombinant Viral-Vectored Vaccines Expressing Plasmodium chabaudi AS Apical Membrane Antigen 1: Mechanisms of Vaccine-Induced Blood-Stage Protection

14 Apr 2012

Abstract excerpt

Apical membrane Ag 1 (AMA1) is one of the leading candidate Ags for inclusion in a subunit vaccine against blood-stage malaria. However, the efficacy of Ab-inducing recombinant AMA1 protein vaccines in phase IIa/b clinical trials remains disappointing. In this article, we describe the development of recombinant human adenovirus serotype 5 and modified vaccinia virus Ankara vectors encoding AMA1 from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Malaria Research and Control
Share to Mosquito-borne diseases and control
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22504652
DOI: 10.4049/jimmunol.1101106

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recombinant Viral-Vectored Vaccines Expressing Plasmodium chabaudi AS Apical Membrane Antigen 1: Mechanisms of Vaccine-Induced Blood-Stage ProtectionPMID 22504652Read ↗

New Candidate Vaccines against Blood-StagePlasmodium falciparumMalaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1Semantic proximity Read ↗

Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.Semantic proximity Read ↗

Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians.Semantic proximity Read ↗

Vaccination of Monkeys with RecombinantPlasmodium falciparumApical Membrane Antigen 1 Confers Protection against Blood-Stage MalariaSemantic proximity Read ↗

Single-Dose Protection against<i>Plasmodium berghei</i>by a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron ASemantic proximity Read ↗

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive IndividualsSemantic proximity Read ↗

Single‐dose immunogenicity and protective efficacy of simian adenoviral vectors against <i>Plasmodium berghei</i>Semantic proximity Read ↗

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.Semantic proximity Read ↗

Expression, Immunogenicity, Histopathology, and Potency of a Mosquito-Based Malaria Transmission-Blocking Recombinant VaccineSemantic proximity Read ↗

Use of viral vectors for the development of vaccinesSemantic proximity Read ↗

Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxSemantic proximity Read ↗

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adultsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.